Systemic Anthrax Lethal Toxin Therapy Produces Regressions of Subcutaneous Human Melanoma Tumors in Athymic Nude Mice
Open Access
- 15 December 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (24) , 7437-7443
- https://doi.org/10.1158/1078-0432.ccr-06-2019
Abstract
Purpose: Anthrax Lethal Toxin (LeTx), composed of protective antigen and lethal factor, catalytically cleaves mitogen-activated protein kinase (MAPK) kinases and inhibits the MAPK signaling pathways. The majority of metastatic melanomas possess the V599E BRAF mutation, which constitutively activates MAPK1/2 signaling. LeTx is cytotoxic to BRAF mutant melanoma cell lines in vitro, whereas most normal cells are resistant to this toxin. In this study, we determine the in vivo potency and safety of systemically administered LeTx.Keywords
This publication has 26 references indexed in Scilit:
- A loop network within the anthrax toxin pore positions the phenylalanine clamp in an active conformationProceedings of the National Academy of Sciences, 2006
- The Antimelanoma Immunocytokine scFvMEL/TNF Shows Reduced Toxicity and Potent Antitumor Activity against Human Tumor XenograftsNeoplasia, 2006
- Management of Metastatic Melanoma 2005Surgical Oncology Clinics of North America, 2006
- Randomized Trials in Melanoma: An UpdateSurgical Oncology Clinics of North America, 2006
- CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.Clinical Cancer Research, 2006
- Targeted Apoptosis Activation with GrB/scFvMEL Modulates Melanoma Growth, Metastatic Spread, Chemosensitivity, and RadiosensitivityNeoplasia, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxinMolecular Cancer Therapeutics, 2005
- A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blastsBlood, 2004
- Anthrax Lethal Factor Proteolysis and Inactivation of MAPK KinaseJournal of Biological Chemistry, 2003